Phase II results of an intraocular steroid delivery system for cataract surgery

Ophthalmology

Volumn 106, Issue 6, 1999, Pages 1172-1177

  Chang, David F ^a,f   Garcia, Ivan H ^b   Hunkeler, John D ^c,e   Minas, Thomas ^d  

^a Altos Eye Physicians   (United States)

^b Omni Eye Specialists   (United States)

^c Hunkeler Eye Centers   (United States)

^d Arizona Ophthal Outpatient Surgery   (United States)

^e Oculex Pharmaceuticals Inc   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PLACEBO; STEROID;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EXTRACAPSULAR CATARACT EXTRACTION; EYE IRRITATION; FEMALE; HUMAN; INFLAMMATION; LENS IMPLANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHACOEMULSIFICATION; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033504874     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90262-2     Document Type: Article

References (16)

1. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears ML, Tarkkanen A, eds. Surgical Pharmacology of the Eye. New York: Raven Press, 1985;83-133.
2. Tennant JL. Cystoid maculopathy: prostaglandins in ophthalmology. In: Emery JM, ed. Current Concepts in Cataract Surgery. St. Louis: C.V. Mosby 1978;360-2.
3. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification. Surv Ophthalmol 1992;37:73-116.
4. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents. Effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol 1984; 102:1453-6.
5. Ferguson VMG, Spalton DJ. Recovery of the blood-aqueous barrier after cataract surgery. Br J Ophthalmol 1991;75:106-10.
6. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986;101: 515-23.
7. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477-80.
8. Ichigashira N, Yamaga N. Intraocular fate of dexamethasone disodium phosphate topically applied to the eyes of rabbits. Steroids 1978;32:615-28.
9. Assil KK, Massry G, Lehmann R, et al. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg 1997;23: 750-7.
10. Bron A, Denis P, Hoang Xuan TC, et al. The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study. Eur J Ophthalmol 1998;8:16-21.
11. Dexamethasone. Reynolds JEF, ed. Martindale: the extra pharmacopoeia, 31st ed. London: Pharmaceutical Press, 1996; 887-9.
12. Bodor N. Designing safer ophthalmic drugs. In: van der Goot H, Domany G, Pallos L, Timmerman H, eds. Trends in Medicinal Chemistry '88. Amsterdam: Elsevier Science Publishers, 1989;145-64.
13. Krupin T, Waltman SR, Becker B. Ocular penetration in rabbits of topically applied dexamethasone. Arch Ophthalmol 1974;92:312-4.
14. Watson D, Noble MJ, Dutton GN, et al. Penetration of topically applied dexamethasone alcohol into human aqueous humor. Arch Ophthalmol 1988;106:686-7.
15. Tan DTH, Chee S-P, Lim L, Lim ASM. Randomized clinical trial of a new dexamethasone delivery system (Surodex™) for treatment of post-cataract surgery inflammation. Ophthalmology 1999;106:223-31.
16. Dada VK, Sindhu N, Sachdev MS. Postoperative intraocular pressure changes with use of different viscoelastics. Ophthalmic Surg 1994;25:540-4.